{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T12:16:38Z","timestamp":1794053798812,"version":"4.8.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-024-03795-2","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T02:02:06Z","timestamp":1723082526000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["NKG2D-bispecific enhances NK and CD8+ T cell antitumor immunity"],"prefix":"10.1007","volume":"73","author":[{"given":"Aurelie","family":"Herault","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy","family":"Mak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefa","family":"de la Cruz-Chuh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Ellerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MaryAnn","family":"Go","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ely","family":"Cosino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Carson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Pichery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myl\u00e8ne","family":"Gador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene Y.","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zora","family":"Modrusan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautham","family":"Gampa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawahar","family":"Sudhamsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher C.","family":"Kemball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi Thu Thao","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhaya","family":"Seshasayee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Piskol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klara","family":"Totpal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shang-Fan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine R.","family":"Kozak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Spiess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1887-7647","authenticated-orcid":false,"given":"Kevin B.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,8]]},"reference":[{"key":"3795_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"3795_CR2","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.2217\/fon-2018-0896","volume":"15","author":"D Eiger","year":"2019","unstructured":"Eiger D, Ponde NF, de Azambuja E (2019) Pertuzumab in HER2-positive early breast cancer: current use and perspectives. Future Oncol 15:1823\u20131843. https:\/\/doi.org\/10.2217\/fon-2018-0896","journal-title":"Future Oncol"},{"key":"3795_CR3","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/BF01518520","volume":"37","author":"GD Lewis","year":"1993","unstructured":"Lewis GD, Figari I, Fendly B, Wong WL, Carter P, Gorman C, Shepard HM (1993) Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother 37:255\u2013263. https:\/\/doi.org\/10.1007\/BF01518520","journal-title":"Cancer Immunol Immunother"},{"key":"3795_CR4","doi-asserted-by":"publisher","first-page":"9330","DOI":"10.1158\/0008-5472.CAN-08-4597","volume":"69","author":"W Scheuer","year":"2009","unstructured":"Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M (2009) Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 69:9330\u20139336. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-4597","journal-title":"Cancer Res"},{"key":"3795_CR5","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1093\/annonc\/mdx002","volume":"28","author":"YJ Bang","year":"2017","unstructured":"Bang YJ, Giaccone G, Im SA et al (2017) First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors. Ann Oncol 28:855\u2013861. https:\/\/doi.org\/10.1093\/annonc\/mdx002","journal-title":"Ann Oncol"},{"key":"3795_CR6","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.clbc.2023.03.007","volume":"23","author":"J O'Shaughnessy","year":"2023","unstructured":"O\u2019Shaughnessy J, Gradishar W, O\u2019Regan R, Gadi V (2023) Risk of recurrence in patients with HER2+ early-stage breast cancer: literature analysis of patient and disease characteristics. Clin Breast Cancer 23:350\u2013362. https:\/\/doi.org\/10.1016\/j.clbc.2023.03.007","journal-title":"Clin Breast Cancer"},{"key":"3795_CR7","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD (2018) Cancer immunotherapy using checkpoint blockade. Science 359:1350\u20131355. https:\/\/doi.org\/10.1126\/science.aar4060","journal-title":"Science"},{"key":"3795_CR8","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1158\/2159-8290.CD-20-1680","volume":"11","author":"P Sharma","year":"2021","unstructured":"Sharma P, Siddiqui BA, Anandhan S, Yadav SS, Subudhi SK, Gao J, Goswami S, Allison JP (2021) The next decade of immune checkpoint therapy. Cancer Discov 11:838\u2013857. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-1680","journal-title":"Cancer Discov"},{"key":"3795_CR9","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1080\/10428194.2022.2095623","volume":"63","author":"S Sasse","year":"2022","unstructured":"Sasse S, Brockelmann PJ, Momotow J et al (2022) AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial. Leuk Lymphoma 63:1871\u20131878. https:\/\/doi.org\/10.1080\/10428194.2022.2095623","journal-title":"Leuk Lymphoma"},{"key":"3795_CR10","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1158\/1078-0432.CCR-18-2337","volume":"25","author":"EY Jen","year":"2019","unstructured":"Jen EY, Xu Q, Schetter A et al (2019) FDA approval: blinatumomab for patients with B-cell precursor acute lymphoblastic leukemia in morphologic remission with minimal residual disease. Clin Cancer Res 25:473\u2013477. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2337","journal-title":"Clin Cancer Res"},{"key":"3795_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13020287","author":"J Middelburg","year":"2021","unstructured":"Middelburg J, Kemper K, Engelberts P, Labrijn AF, Schuurman J, van Hall T (2021) Overcoming challenges for CD3-bispecific antibody therapy in solid tumors. Cancers. https:\/\/doi.org\/10.3390\/cancers13020287","journal-title":"Cancers"},{"key":"3795_CR12","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1126\/science.285.5428.727","volume":"285","author":"S Bauer","year":"1999","unstructured":"Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, Spies T (1999) Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285:727\u2013729. https:\/\/doi.org\/10.1126\/science.285.5428.727","journal-title":"Science"},{"key":"3795_CR13","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/eji.200940278","volume":"41","author":"C Kuylenstierna","year":"2011","unstructured":"Kuylenstierna C, Bjorkstrom NK, Andersson SK et al (2011) NKG2D performs two functions in invariant NKT cells: direct TCR-independent activation of NK-like cytolysis and co-stimulation of activation by CD1d. Eur J Immunol 41:1913\u20131923. https:\/\/doi.org\/10.1002\/eji.200940278","journal-title":"Eur J Immunol"},{"key":"3795_CR14","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1158\/2326-6066.CIR-15-0098","volume":"3","author":"LL Lanier","year":"2015","unstructured":"Lanier LL (2015) NKG2D receptor and its ligands in host defense. Cancer Immunol Res 3:575\u2013582. https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0098","journal-title":"Cancer Immunol Res"},{"key":"3795_CR15","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/85321","volume":"2","author":"V Groh","year":"2001","unstructured":"Groh V, Rhinehart R, Randolph-Habecker J, Topp MS, Riddell SR, Spies T (2001) Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol 2:255\u2013260. https:\/\/doi.org\/10.1038\/85321","journal-title":"Nat Immunol"},{"key":"3795_CR16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/s1074-7613(02)00333-3","volume":"17","author":"AM Jamieson","year":"2002","unstructured":"Jamieson AM, Diefenbach A, McMahon CW, Xiong N, Carlyle JR, Raulet DH (2002) The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 17:19\u201329. https:\/\/doi.org\/10.1016\/s1074-7613(02)00333-3","journal-title":"Immunity"},{"key":"3795_CR17","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/35093109","volume":"413","author":"A Diefenbach","year":"2001","unstructured":"Diefenbach A, Jensen ER, Jamieson AM, Raulet DH (2001) Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 413:165\u2013171. https:\/\/doi.org\/10.1038\/35093109","journal-title":"Nature"},{"key":"3795_CR18","doi-asserted-by":"publisher","first-page":"11521","DOI":"10.1073\/pnas.201238598","volume":"98","author":"A Cerwenka","year":"2001","unstructured":"Cerwenka A, Baron JL, Lanier LL (2001) Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci USA 98:11521\u201311526. https:\/\/doi.org\/10.1073\/pnas.201238598","journal-title":"Proc Natl Acad Sci USA"},{"key":"3795_CR19","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1084\/jem.20050994","volume":"202","author":"MJ Smyth","year":"2005","unstructured":"Smyth MJ, Swann J, Cretney E, Zerafa N, Yokoyama WM, Hayakawa Y (2005) NKG2D function protects the host from tumor initiation. J Exp Med 202:583\u2013588. https:\/\/doi.org\/10.1084\/jem.20050994","journal-title":"J Exp Med"},{"key":"3795_CR20","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.immuni.2008.02.016","volume":"28","author":"N Guerra","year":"2008","unstructured":"Guerra N, Tan YX, Joncker NT et al (2008) NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 28:571\u2013580. https:\/\/doi.org\/10.1016\/j.immuni.2008.02.016","journal-title":"Immunity"},{"key":"3795_CR21","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200920","author":"KE Pauken","year":"2021","unstructured":"Pauken KE, Shahid O, Lagattuta KA et al (2021) Single-cell analyses identify circulating anti-tumor CD8 T cells and markers for their enrichment. J Exp Med. https:\/\/doi.org\/10.1084\/jem.20200920","journal-title":"J Exp Med"},{"key":"3795_CR22","doi-asserted-by":"publisher","first-page":"6447","DOI":"10.1158\/1078-0432.CCR-18-1139","volume":"24","author":"J Li","year":"2018","unstructured":"Li J, Ybarra R, Mak J et al (2018) IFNgamma-induced chemokines are required for CXCR3-mediated T-cell recruitment and antitumor efficacy of anti-HER2\/CD3 bispecific antibody. Clin Cancer Res 24:6447\u20136458. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1139","journal-title":"Clin Cancer Res"},{"key":"3795_CR23","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid P, Adams S, Rugo HS et al (2018) Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. New Engl J Med 379:2108\u20132121. https:\/\/doi.org\/10.1056\/NEJMoa1809615","journal-title":"New Engl J Med"},{"key":"3795_CR24","doi-asserted-by":"crossref","unstructured":"Trina Formolo ML, Michaella L, Lisa K, Scott L, Karen P, Lisa M, Kurt B, Michael B, Darryl D, John S (2015) Determination of the NISTmAb Primary Structure. In: John E. Schiel DLD, Oleg V. Borisov (eds) State-of-the-art and emerging technologies for therapeutic monoclonal antibody characterization Volume 2. Biopharmaceutical Characterization: The NISTmAb Case Study. ACS Publications. pp. 1\u201362","DOI":"10.1021\/bk-2015-1201.ch001"},{"key":"3795_CR25","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/nbt.2621","volume":"31","author":"C Spiess","year":"2013","unstructured":"Spiess C, Merchant M, Huang A et al (2013) Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies. Nat Biotechnol 31:753\u2013758. https:\/\/doi.org\/10.1038\/nbt.2621","journal-title":"Nat Biotechnol"},{"key":"3795_CR26","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1080\/19420862.2018.1532767","volume":"11","author":"TN Lombana","year":"2019","unstructured":"Lombana TN, Matsumoto ML, Berkley AM et al (2019) High-resolution glycosylation site-engineering method identifies MICA epitope critical for shedding inhibition activity of anti-MICA antibodies. MAbs 11:75\u201393. https:\/\/doi.org\/10.1080\/19420862.2018.1532767","journal-title":"MAbs"},{"key":"3795_CR27","doi-asserted-by":"publisher","first-page":"9280","DOI":"10.1158\/0008-5472.CAN-08-1776","volume":"68","author":"GD Lewis Phillips","year":"2008","unstructured":"Lewis Phillips GD, Li G, Dugger DL et al (2008) Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 68:9280\u20139290. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-1776","journal-title":"Cancer Res"},{"key":"3795_CR28","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/bs.acr.2019.05.001","volume":"144","author":"A Toker","year":"2019","unstructured":"Toker A, Ohashi PS (2019) Expression of costimulatory and inhibitory receptors in FoxP3(+) regulatory T cells within the tumor microenvironment: Implications for combination immunotherapy approaches. Adv Cancer Res 144:193\u2013261. https:\/\/doi.org\/10.1016\/bs.acr.2019.05.001","journal-title":"Adv Cancer Res"},{"key":"3795_CR29","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2020107333","volume":"40","author":"B Pal","year":"2021","unstructured":"Pal B, Chen Y, Vaillant F et al (2021) A single-cell RNA expression atlas of normal, preneoplastic and tumorigenic states in the human breast. EMBO J 40:e107333. https:\/\/doi.org\/10.15252\/embj.2020107333","journal-title":"EMBO J"},{"key":"3795_CR30","doi-asserted-by":"publisher","first-page":"ra108","DOI":"10.1126\/scisignal.aab2724","volume":"8","author":"L Quatrini","year":"2015","unstructured":"Quatrini L, Molfetta R, Zitti B et al (2015) Ubiquitin-dependent endocytosis of NKG2D-DAP10 receptor complexes activates signaling and functions in human NK cells. Sci Signal 8:ra108. https:\/\/doi.org\/10.1126\/scisignal.aab2724","journal-title":"Sci Signal"},{"key":"3795_CR31","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.cyto.2008.01.003","volume":"42","author":"C Zhang","year":"2008","unstructured":"Zhang C, Zhang J, Niu J, Zhang J, Tian Z (2008) Interleukin-15 improves cytotoxicity of natural killer cells via up-regulating NKG2D and cytotoxic effector molecule expression as well as STAT1 and ERK1\/2 phosphorylation. Cytokine 42:128\u2013136. https:\/\/doi.org\/10.1016\/j.cyto.2008.01.003","journal-title":"Cytokine"},{"key":"3795_CR32","doi-asserted-by":"publisher","first-page":"5561","DOI":"10.1158\/0008-5472.CAN-13-3622-T","volume":"74","author":"TT Junttila","year":"2014","unstructured":"Junttila TT, Li J, Johnston J et al (2014) Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cells. Cancer Res 74:5561\u20135571. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-3622-T","journal-title":"Cancer Res"},{"key":"3795_CR33","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1158\/1535-7163.1585.3.12","volume":"3","author":"M Tanner","year":"2004","unstructured":"Tanner M, Kapanen AI, Junttila T, Raheem O, Grenman S, Elo J, Elenius K, Isola J (2004) Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Mol Cancer Ther 3:1585\u20131592","journal-title":"Mol Cancer Ther"},{"key":"3795_CR34","unstructured":"Junttila TT, Lutzker S (2020) Treatment of cancer with her2xcd3 bispecific antibodies in combination with anti-her2 mab. GENENTECH INC (US), HOFFMANN LA ROCHE (CH)"},{"key":"3795_CR35","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1158\/1078-0432.CCR-16-1272","volume":"23","author":"NH Segal","year":"2017","unstructured":"Segal NH, Logan TF, Hodi FS et al (2017) Results from an integrated safety analysis of urelumab, an agonist Anti-CD137 monoclonal antibody. Clin Cancer Res 23:1929\u20131936. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1272","journal-title":"Clin Cancer Res"},{"key":"3795_CR36","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1056\/NEJMoa063842","volume":"355","author":"G Suntharalingam","year":"2006","unstructured":"Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N (2006) Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355:1018\u20131028. https:\/\/doi.org\/10.1056\/NEJMoa063842","journal-title":"N Engl J Med"},{"key":"3795_CR37","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s43018-019-0004-z","volume":"1","author":"L Wu","year":"2020","unstructured":"Wu L, Seung E, Xu L et al (2020) Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation. Nat Cancer 1:86\u201398. https:\/\/doi.org\/10.1038\/s43018-019-0004-z","journal-title":"Nat Cancer"},{"key":"3795_CR38","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/j.1476-5381.2010.00922.x","volume":"161","author":"D Eastwood","year":"2010","unstructured":"Eastwood D, Findlay L, Poole S, Bird C, Wadhwa M, Moore M, Burns C, Thorpe R, Stebbings R (2010) Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. Br J Pharmacol 161:512\u2013526. https:\/\/doi.org\/10.1111\/j.1476-5381.2010.00922.x","journal-title":"Br J Pharmacol"},{"key":"3795_CR39","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1158\/1535-7163.MCT-19-0608","volume":"19","author":"SK Ho","year":"2020","unstructured":"Ho SK, Xu Z, Thakur A et al (2020) Epitope and Fc-mediated cross-linking, but not high affinity, are critical for antitumor activity of CD137 agonist antibody with reduced liver toxicity. Mol Cancer Ther 19:1040\u20131051. https:\/\/doi.org\/10.1158\/1535-7163.MCT-19-0608","journal-title":"Mol Cancer Ther"},{"key":"3795_CR40","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1158\/1078-0432.CCR-17-1847","volume":"24","author":"T Bartkowiak","year":"2018","unstructured":"Bartkowiak T, Jaiswal AR, Ager CR et al (2018) Activation of 4\u20131BB on liver myeloid cells triggers hepatitis via an interleukin-27-dependent pathway. Clin Cancer Res 24:1138\u20131151. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-1847","journal-title":"Clin Cancer Res"},{"key":"3795_CR41","doi-asserted-by":"publisher","first-page":"12099","DOI":"10.1038\/s41598-017-12256-z","volume":"7","author":"J Zhang","year":"2017","unstructured":"Zhang J, Jiao Y, Hou S, Tian T, Yuan Q, Hao H, Wu Z, Bao X (2017) S100A4 contributes to colitis development by increasing the adherence of Citrobacter rodentium in intestinal epithelial cells. Sci Rep 7:12099. https:\/\/doi.org\/10.1038\/s41598-017-12256-z","journal-title":"Sci Rep"},{"key":"3795_CR42","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav5989","author":"C Claus","year":"2019","unstructured":"Claus C, Ferrara C, Xu W et al (2019) Tumor-targeted 4\u20131BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.aav5989","journal-title":"Sci Transl Med"},{"key":"3795_CR43","doi-asserted-by":"publisher","first-page":"eaaw7888","DOI":"10.1126\/scitranslmed.aaw7888","volume":"12","author":"D Skokos","year":"2020","unstructured":"Skokos D, Waite JC, Haber L et al (2020) A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies. Sci Transl Med. 12:eaaw7888. https:\/\/doi.org\/10.1126\/scitranslmed.aaw7888","journal-title":"Sci Transl Med."},{"key":"3795_CR44","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/978-981-32-9717-3_7","volume":"1189","author":"JB Wing","year":"2019","unstructured":"Wing JB, Tay C, Sakaguchi S (2019) Control of regulatory T cells by Co-signal molecules. Adv Exp Med Biol 1189:179\u2013210. https:\/\/doi.org\/10.1007\/978-981-32-9717-3_7","journal-title":"Adv Exp Med Biol"},{"key":"3795_CR45","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s12276-021-00576-0","volume":"53","author":"JH Park","year":"2021","unstructured":"Park JH, Lee HK (2021) Function of gammadelta T cells in tumor immunology and their application to cancer therapy. Exp Mol Med 53:318\u2013327. https:\/\/doi.org\/10.1038\/s12276-021-00576-0","journal-title":"Exp Mol Med"},{"key":"3795_CR46","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1038\/leu.2011.42","volume":"25","author":"S Stamova","year":"2011","unstructured":"Stamova S, Cartellieri M, Feldmann A et al (2011) Simultaneous engagement of the activatory receptors NKG2D and CD3 for retargeting of effector cells to CD33-positive malignant cells. Leukemia 25:1053\u20131056. https:\/\/doi.org\/10.1038\/leu.2011.42","journal-title":"Leukemia"},{"key":"3795_CR47","doi-asserted-by":"publisher","first-page":"10121","DOI":"10.1158\/0008-5472.CAN-10-1047","volume":"70","author":"HM Cho","year":"2010","unstructured":"Cho HM, Rosenblatt JD, Tolba K, Shin SJ, Shin DS, Calfa C, Zhang Y, Shin SU (2010) Delivery of NKG2D ligand using an anti-HER2 antibody-NKG2D ligand fusion protein results in an enhanced innate and adaptive antitumor response. Cancer Res 70:10121\u201310130. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-1047","journal-title":"Cancer Res"},{"key":"3795_CR48","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1182\/blood-2005-05-2177","volume":"107","author":"EP von Strandmann","year":"2006","unstructured":"von Strandmann EP, Hansen HP, Reiners KS et al (2006) A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo. Blood 107:1955\u20131962. https:\/\/doi.org\/10.1182\/blood-2005-05-2177","journal-title":"Blood"},{"key":"3795_CR49","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1211220","volume":"5","author":"M Vyas","year":"2016","unstructured":"Vyas M, Schneider AC, Shatnyeva O et al (2016) Mono- and dual-targeting triplebodies activate natural killer cells and have anti-tumor activity in vitro and in vivo against chronic lymphocytic leukemia. Oncoimmunology 5:e1211220. https:\/\/doi.org\/10.1080\/2162402X.2016.1211220","journal-title":"Oncoimmunology"},{"key":"3795_CR50","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1097\/CJI.0000000000000320","volume":"43","author":"Y Wang","year":"2020","unstructured":"Wang Y, Li H, Xu W, Pan M, Qiao C, Cai J, Xu J, Wang M, Zhang J (2020) BCMA-targeting bispecific antibody that simultaneously stimulates NKG2D-enhanced efficacy against multiple myeloma. J Immunother 43:175\u2013188. https:\/\/doi.org\/10.1097\/CJI.0000000000000320","journal-title":"J Immunother"},{"key":"3795_CR51","doi-asserted-by":"publisher","first-page":"1854529","DOI":"10.1080\/2162402X.2020.1854529","volume":"10","author":"A Raynaud","year":"2020","unstructured":"Raynaud A, Desrumeaux K, Vidard L, Termine E, Baty D, Chames P, Vigne E, Kerfelec B (2020) Anti-NKG2D single domain-based antibodies for the modulation of anti-tumor immune response. Oncoimmunology 10:1854529. https:\/\/doi.org\/10.1080\/2162402X.2020.1854529","journal-title":"Oncoimmunology"},{"key":"3795_CR52","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1097\/CJI.0000000000000215","volume":"41","author":"T Wang","year":"2018","unstructured":"Wang T, Sun F, Wang Y et al (2018) NKG2D Immunoligand rG7S-MICA enhances NK Cell-mediated immunosurveillance in colorectal carcinoma. J Immunother 41:109\u2013117. https:\/\/doi.org\/10.1097\/CJI.0000000000000215","journal-title":"J Immunother"},{"key":"3795_CR53","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1002\/ijc.28609","volume":"134","author":"A Rothe","year":"2014","unstructured":"Rothe A, Jachimowicz RD, Borchmann S et al (2014) The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma. Int J Cancer 134:2829\u20132840. https:\/\/doi.org\/10.1002\/ijc.28609","journal-title":"Int J Cancer"},{"key":"3795_CR54","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s00432-019-02865-8","volume":"145","author":"Y Han","year":"2019","unstructured":"Han Y, Sun F, Zhang X et al (2019) CD24 targeting bi-specific antibody that simultaneously stimulates NKG2D enhances the efficacy of cancer immunotherapy. J Cancer Res Clin Oncol 145:1179\u20131190. https:\/\/doi.org\/10.1007\/s00432-019-02865-8","journal-title":"J Cancer Res Clin Oncol"},{"key":"3795_CR55","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/leu.2011.288","volume":"26","author":"C Kellner","year":"2012","unstructured":"Kellner C, Hallack D, Glorius P et al (2012) Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicity. Leukemia 26:830\u2013834. https:\/\/doi.org\/10.1038\/leu.2011.288","journal-title":"Leukemia"},{"key":"3795_CR56","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1002\/eji.201847550","volume":"48","author":"Y Zou","year":"2018","unstructured":"Zou Y, Luo W, Guo J, Luo Q, Deng M, Lu Z, Fang Y, Zhang CC (2018) NK cell-mediated anti-leukemia cytotoxicity is enhanced using a NKG2D ligand MICA and anti-CD20 scfv chimeric protein. Eur J Immunol 48:1750\u20131763. https:\/\/doi.org\/10.1002\/eji.201847550","journal-title":"Eur J Immunol"},{"key":"3795_CR57","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1230","volume":"9","author":"S Xing","year":"2020","unstructured":"Xing S, Ferrari de Andrade L (2020) NKG2D and MICA\/B shedding: a \u2018tag game\u2019 between NK cells and malignant cells. Clin Transl Immunology 9:e1230. https:\/\/doi.org\/10.1002\/cti2.1230","journal-title":"Clin Transl Immunology"},{"key":"3795_CR58","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aai8904","author":"J Zuo","year":"2017","unstructured":"Zuo J, Willcox CR, Mohammed F et al (2017) A disease-linked ULBP6 polymorphism inhibits NKG2D-mediated target cell killing by enhancing the stability of NKG2D ligand binding. Sci Signal. https:\/\/doi.org\/10.1126\/scisignal.aai8904","journal-title":"Sci Signal"},{"key":"3795_CR59","doi-asserted-by":"publisher","first-page":"ARTN1820","DOI":"10.3389\/fimmu.2018.01820","volume":"9","author":"JM Zuo","year":"2018","unstructured":"Zuo JM, Mohammed F, Moss P (2018) The Biological Influence and Clinical Relevance of Polymorphism Within the NKG2D Ligands. Front Immunol. 9:ARTN1820","journal-title":"Front Immunol."}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03795-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-024-03795-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03795-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T18:08:14Z","timestamp":1726510094000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-024-03795-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,8]]},"references-count":59,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["3795"],"URL":"https:\/\/doi.org\/10.1007\/s00262-024-03795-2","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,8]]},"assertion":[{"value":"16 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors employed by Genentech declare that they have ownership interests in and\/or patents with Genentech.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All studies were conducted in accordance with the American Association of Laboratory Animal Care guidelines. Experimental studies were conducted with approval of the IACUC at Genentech.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This manuscript does not contain patient personal data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"209"}}